EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Pharmacokinetics and Bioequivalence of 2 Deutetrabenazine Tablets in Healthy Chinese Volunteers Under Fasting and Fed Conditions

Dayong Xu, Pengkai Wang, Yuan Li, Ping Zhang, Liying Wei, Xiaolian Xiong, Xin Li

Clinical Pharmacology in Drug Development · 2026-03 · 15 (3)

DOI: 10.1002/cpdd.70054 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 22.03.2026. Verfasst von Dayong Xu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School, Hunan University of Chinese Medicine, Changsha, Hunan, P. R. China. Hauptthemen laut MEDLINE: Adrenergic Uptake Inhibitors, Fasting, Tetrabenazine. Die Arbeit nennt 26 Literaturangaben. Gefördert von: by Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Deutetrabenazine, a deuterated vesicular monoamine transporter 2 (VMAT2) inhibitor, is approved for the treatment of Huntington's disease (HD)‐related chorea and tardive dyskinesia (TD). However, pharmacokinetics (PK) and bioequivalence (BE) evidence in the Chinese population has been lacking. This single‐center, randomized, open‐label, single‐dose, two‐formulation, four‐period, fully replicated crossover study evaluated the PK, BE, and safety of test and reference deutetrabenazine 12 mg tablets under fasting and fed conditions in healthy Chinese volunteers. A total of 90 subjects were enrolled (40 fasting; 50 fed), and 88 completed the study. Plasma concentrations of deutetrabenazine and its active metabolites d6‐α‐dihydrotetrabenazine (d6‐α‐HTBZ) and d6‐β‐dihydrotetrabenazine (d6‐β‐HTBZ) were quantified using a validated liquid chromatography‐tandem mass spectrometry method. BE was assessed using average bioequivalence (ABE) or reference‐scaled average bioequivalence (RSABE) according to within‐subject variability. Under fasting conditions, RSABE was applied for maximum plasma concentration (C max ) and met equivalence criteria (point estimate within 80%–125%, upper confidence interval bound ≤ 0); under fed conditions, as well as for all remaining PK parameters, ABE criteria were met with the 90% confidence interval within the 80%–125% range. Both formulations were well tolerated, with only mild and transient adverse events and no serious safety findings. These results demonstrate that the test and reference deutetrabenazine tablets are bioequivalent in healthy Chinese adults under both nutritional states.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenergic Uptake InhibitorsFastingTetrabenazineAdultFemaleHumansMaleYoung AdultAdministration, OralArea Under CurveChromatography, LiquidCross-Over StudiesHealthy VolunteersTabletsTandem Mass SpectrometryTherapeutic EquivalencyVesicular Monoamine Transport ProteinsEast Asian People

Stichwörter der Autor:innen

Huntington's diseaseVMAT2 inhibitorbioequivalencedeutetrabenazinepharmacokineticstardive dyskinesia

Substanzen

Adrenergic Uptake InhibitorsdeutetrabenazinedihydrotetrabenazineTabletsTetrabenazineVesicular Monoamine Transport Proteins

Autor:innen und Institutionen

  • Graduate School, Hunan University of Chinese Medicine, Changsha, Hunan, P. R. China.
  • Department of Pharmacy, The Third Hospital of Changsha, Changsha, Hunan, P. R. China.
  • School of Biomedical Sciences, Hunan University, Changsha, Hunan, P. R. China.
  • Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd, Jiangsu, Nanjing, P. R. China.

Förderung

  • by Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd.

Zitieren

APA

Xu, D., Wang, P., Li, Y., Zhang, P., Wei, L., Xiong, X., & Li, X. (2026). Pharmacokinetics and Bioequivalence of 2 Deutetrabenazine Tablets in Healthy Chinese Volunteers Under Fasting and Fed Conditions. Clinical Pharmacology in Drug Development, 15(3). https://doi.org/10.1002/cpdd.70054

Vancouver

Xu D, Wang P, Li Y, Zhang P, Wei L, Xiong X, et al. Pharmacokinetics and Bioequivalence of 2 Deutetrabenazine Tablets in Healthy Chinese Volunteers Under Fasting and Fed Conditions. Clinical Pharmacology in Drug Development. 2026;15(3). doi:10.1002/cpdd.70054

BibTeX
@article{Xu2026,
  author = {Xu, Dayong and Wang, Pengkai and Li, Yuan and Zhang, Ping and Wei, Liying and Xiong, Xiaolian and Li, Xin},
  title = {Pharmacokinetics and Bioequivalence of 2 Deutetrabenazine Tablets in Healthy Chinese Volunteers Under Fasting and Fed Conditions},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2026},
  volume = {15},
  number = {3},
  doi = {10.1002/cpdd.70054}
}
Kostenlos starten →